How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pyrotinib-plus-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

pyrotinib plus capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pyrotinib plus capecitabine (pyrotinib plus capecitabine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor, Antimetabolite. Area: Oncology.

phase 3 Tyrosine kinase inhibitor, Antimetabolite HER2/neu, Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

pyrotinib plus capecitabine (pyrotinib plus capecitabine) — Henan Cancer Hospital. Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while capecitabine is a prodrug of fluorouracil, an antimetabolite that interferes with DNA synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pyrotinib plus capecitabine TARGET	pyrotinib plus capecitabine	Henan Cancer Hospital	phase 3	Tyrosine kinase inhibitor, Antimetabolite	HER2/neu, Thymidylate synthase
Sunitinib + Capecitabine	Sunitinib + Capecitabine	Pfizer	phase 3	tyrosine kinase inhibitor, antimetabolite	VEGFR, PDGFR, c-KIT, thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor, Antimetabolite class)

Henan Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pyrotinib plus capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/pyrotinib-plus-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab